Collectively, these findings demonstrate the immunotherapeutic potential of SSRIs in a broad range of cancers and suggest that SERT regulates CD8 T cell antitumor immunity through a possible intratumoral serotonin axis (Figure 1B). The gene discussed is SLC6A4; the disease is cancer.